Steven Cohen’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$286K Hold
14,200
– – ﹤0.01% 3362
2026
Q2
$359K Buy
14,200
+500
+4% +$11K ﹤0.01% 3319
2026
Q1
$305K Buy
+13,700
New +$327K ﹤0.01% 3358
2018
Q2
– Sell
-400,000
Closed -$8.99M – 943
2018
Q1
$8.99M Buy
+400,000
New +$11.1M 0.04% 448
2017
Q4
– Sell
-500,000
Closed -$18.8M – 882
2017
Q3
$18.8M Buy
+500,000
New +$16.3M 0.08% 273

Other funds holding ACAD

Steven Cohen's ACAD Position: Q3 2026 in Review

Steven Cohen reduced its Acadia Pharmaceuticals (ACAD) stake by 53% in Q3 2026, selling an estimated $34.8M and leaving 1,135,983 shares worth $22.9M. The position accounts for 0.03% of the portfolio, ranked #838.

Steven Cohen first reported a position in ACAD in Q2 2014 and has held it in 40 quarters since. The position peaked at $97.9M in Q1 2018. 348 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

  • Steven Cohen held 1,135,983 shares of Acadia Pharmaceuticals worth $22.9M as of Q3 2026.
  • Steven Cohen sold 1,297,185 Acadia Pharmaceuticals shares in Q3 2026, an estimated $34.8M.
  • Acadia Pharmaceuticals made up 0.03% of Steven Cohen's portfolio in Q3 2026, its #838 holding.
  • Steven Cohen first reported a position in Acadia Pharmaceuticals in Q2 2014 and has held it in 40 quarters since.
  • Steven Cohen's Acadia Pharmaceuticals position peaked at $97.9M in Q1 2018.
  • 348 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on Point72 Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.